Sumitomo Mitsui Trust Expands Stake in AbbVie Amid Strong Market Activity

Sumitomo Mitsui Trust Group Inc. has increased its holdings in AbbVie Inc. (NYSE: ABBV) by 1.6% during the third quarter of 2023. This information comes from the company’s recent Form 13F filing with the Securities & Exchange Commission. Following the purchase of an additional 66,358 shares, the fund now owns a total of 4,256,071 shares, which represents about 0.6% of its overall portfolio. AbbVie ranks as the 25th largest position for Sumitomo Mitsui Trust Group, with its holdings valued at approximately $985.45 million.

The move by Sumitomo Mitsui Trust Group comes as several other institutional investors have also adjusted their positions in AbbVie. Notably, Norges Bank acquired a stake valued at around $4.29 billion in the second quarter, while Laurel Wealth Advisors LLC significantly increased its ownership by 18,384.4%, now holding 5,705,964 shares worth about $1.06 billion after purchasing 5,675,095 additional shares. Assenagon Asset Management S.A. also made headlines by boosting its holdings by 550.9%, acquiring an additional 3,666,521 shares during the same period.

Vanguard Group Inc., a well-known name in investment, increased its position in AbbVie by 1.9% and now owns 177,298,707 shares, valued at approximately $32.91 billion. Additionally, Kingstone Capital Partners Texas LLC entered a new position in AbbVie worth about $581.82 million. Currently, institutional investors and hedge funds own 70.23% of AbbVie’s stock.

AbbVie Stock Performance and Dividend Increase

On Monday, AbbVie shares opened at $220.06. The company’s 50-day simple moving average stands at $226.59, while the 200-day simple moving average is at $215.53. Over the past year, AbbVie has experienced a low of $164.39 and a high of $244.81. With a market capitalization of $388.93 billion, the company holds a price-to-earnings (P/E) ratio of 166.71 and a P/E/G ratio of 0.92.

In a positive development for shareholders, AbbVie announced a quarterly dividend of $1.73, set to be paid on February 17, 2024. Shareholders on record as of January 16, 2024 will benefit from this increase, which marks a rise from the previous quarterly dividend of $1.64. The annualized dividend now stands at $6.92, yielding approximately 3.1%. AbbVie’s current dividend payout ratio is an exceptionally high 496.97%.

Analyst Insights and Ratings Changes

AbbVie has garnered attention from several research analysts recently. HSBC Global Research upgraded its rating from “hold” to “strong buy” in a report on December 10, 2023. Guggenheim revised its price target on AbbVie shares from $227.00 to $242.00 while maintaining a “buy” rating. Similarly, Bank of America increased its target price from $220.00 to $251.00 with a “neutral” rating, reflecting optimism about the stock’s performance.

Moreover, Citigroup adjusted its price target downward from $240.00 to $235.00, while maintaining a “neutral” stance. Presently, three analysts rate AbbVie stock as a “strong buy,” thirteen as a “buy,” and eight as a “hold.” According to data from MarketBeat.com, the average analyst rating for AbbVie stands at “moderate buy,” with an average target price of $246.89.

In summary, Sumitomo Mitsui Trust Group’s increased investment in AbbVie reflects broader market confidence in the biopharmaceutical company. With a strong institutional backing, an upward trend in share performance, and an increase in dividends, AbbVie appears well-positioned for continued growth in the competitive pharmaceutical landscape.